Psoriasis drug study dives into genetic changes

NCT ID NCT06506916

Ongoing Knowledge-focused Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 25 times

Summary

This study looks at how the drug bimekizumab affects gene activity in people with moderate to severe plaque psoriasis, with or without psoriatic arthritis. Researchers will take small skin samples to measure changes in gene expression over 48 weeks. The goal is to better understand how the drug works at a molecular level, not to directly treat or cure the disease. About 89 adults are taking part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Ps0039 40072

Freiburg im Breisgau, Germany
Ps0039 40287

Frankfurt am Main, Germany
Ps0039 40347

Lodz, Poland
Ps0039 40515

Berlin, Germany
Ps0039 40625

Warsaw, Poland
Ps0039 40757

Poznan, Poland
Ps0039 40761

Warsaw, Poland
Ps0039 40773

Wroclaw, Poland
Ps0039 50110

Ann Arbor, Michigan, 48109, United States
Ps0039 50140

Birmingham, Alabama, 35233, United States
Ps0039 50162

Fountain Valley, California, 92708, United States
Ps0039 50283

Tampa, Florida, 33613, United States
Ps0039 50491

Pittsburgh, Pennsylvania, 15213-2536, United States
Ps0039 50643

Rochester, New York, 14623, United States

Conditions

Explore the condition pages connected to this study.

MODERATE TO SEVERE PLAQUE PSORIASIS MODERATE TO SEVERE PLAQUE PSORIASIS PSORIATIC ARTHRITIS